Understanding the Complex Peptide Cyclization of MT-II

In the peptide API market, Melanotan II (CAS No: 121062-08-6) represents a masterpiece of structural engineering. It is not a simple linear peptide; rather, it is a synthetically modified cyclic heptapeptide analog of the endogenous α-melanocyte-stimulating hormone (α-MSH). By incorporating a stable lactam ring junction between Asp³ and Lys⁸ residues and substituting the wild-type L-configuration with D-Phenylalanine at position 7, the molecule acquires outstanding resistance to degradation by proteolytic enzymes in systemic circulation.

As an authoritative manufacturer, Shaanxi Sunrise Pharmaceutical Co., Ltd. implements an intensive three-step preparative HPLC purification regime to separate non-cyclized linear intermediates. This rigorous approach guarantees a correct secondary structure with full intramolecular coordination, delivering reproducible clinical and in vitro research data.

For high-sensitivity metabolic and neurological research, utilizing sub-standard peptide powders introduces significant experimental variables and unwanted toxicity. High concentrations of residual Trifluoroacetic Acid (TFA) are cytotoxic, inducing cell apoptosis in localized neural cultures. Furthermore, bacterial endotoxin contamination triggers inflammatory cytokine surges, masking the target pathways.

Shaanxi Sunrise has optimized the ion-exchange synthesis cycle to replace cytotoxic TFA ions with biocompatible acetate salt complexes. This reduces residual TFA to less than 1.0% while strictly limiting endotoxins to ≤ 0.05 EU/mg, protecting cellular viability in long-term exposure studies.